Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey T Kuethe

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Organic Letters|June 29, 2023
Synthesis of a Complex and Highly Potent PCSK9 InhibitorJeffrey T Kuethe, Joshua Lee, David Thaisrivongs, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2016
The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitorsJason M Cox, Hong D Chu, Jeffrey T Kuethe, et al.
The Journal of Organic Chemistry|August 16, 2011
Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycleZhiguo J Song, David M Tellers, Michel Journet, et al.
Bioorganic & Medicinal Chemistry Letters|November 8, 2015
Structure-activity-relationship of amide and sulfonamide analogs of omarigliptinPing Chen, Dennis Feng, Xiaoxia Qian, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of AnemiaJohn S Debenham, Christina Madsen-Duggan, Matthew J Clements, et al.
Journal of Medicinal Chemistry|March 26, 2014
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetesTesfaye Biftu, Ranabir Sinha-Roy, Ping Chen, et al.
Journal of Medicinal Chemistry|October 27, 2021
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 InhibitorsThomas J Tucker, Mark W Embrey, Candice Alleyne, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid MoietyShuwen He, Qingmei Hong, Zhong Lai, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2019
Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moietyShuwen He, Zhong Lai, Qingmei Hong, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Organic Letters|June 29, 2023
Synthesis of a Complex and Highly Potent PCSK9 InhibitorJeffrey T Kuethe, Joshua Lee, David Thaisrivongs, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2016
The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitorsJason M Cox, Hong D Chu, Jeffrey T Kuethe, et al.
The Journal of Organic Chemistry|August 16, 2011
Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycleZhiguo J Song, David M Tellers, Michel Journet, et al.
Bioorganic & Medicinal Chemistry Letters|November 8, 2015
Structure-activity-relationship of amide and sulfonamide analogs of omarigliptinPing Chen, Dennis Feng, Xiaoxia Qian, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2013
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitorsJohn S Debenham, Thomas H Graham, Andreas Verras, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of AnemiaJohn S Debenham, Christina Madsen-Duggan, Matthew J Clements, et al.
Journal of Medicinal Chemistry|March 26, 2014
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetesTesfaye Biftu, Ranabir Sinha-Roy, Ping Chen, et al.
Journal of Medicinal Chemistry|October 27, 2021
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 InhibitorsThomas J Tucker, Mark W Embrey, Candice Alleyne, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid MoietyShuwen He, Qingmei Hong, Zhong Lai, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2019
Benzimidazole-based DGAT1 inhibitors with a [3.1.0] bicyclohexane carboxylic acid moietyShuwen He, Zhong Lai, Qingmei Hong, et al.
Pageof 5